The LPC-Study, sponsored by the University Hospital Basel, aims to evaluate the efficacy of LSD in alleviating psychosocial distress in terminally ill patients. Given the increasing interest in psychedelic-assisted therapies, this study positions itself within a burgeoning market for mental health treatments, particularly in palliative care. The potential to demonstrate significant improvements in quality of life and pain management could attract attention from pharmaceutical companies seeking to expand their portfolios in this area. However, the competitive landscape includes other psychedelic compounds like psilocybin, which are also being investigated for similar indications. Diligence should focus on regulatory pathways, potential market access challenges, and the evolving public perception of psychedelics in therapeutic contexts.